Literature DB >> 10460352

Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation.

F Keil1, P Kalhs, X Chen, O A Haas, G Fritsch, A Chott, K Lechner, K Moser, J Ackermann, W Rabitsch, N Worel, C Mannhalter, H T Greinix.   

Abstract

A large group of patients relapsing after allogeneic bone marrow transplantation (BMT) have obtained remission after infusion of leukocytes from their original donor, suggesting a graft-versus-myeloma effect. However, side effects such as graft-versus-host disease and myelosuppression are severe, and sometimes fatal, complications of this therapeutic approach. Previously we demonstrated that patients with leukemia who lack donor hematopoiesis in relapse after BMT experience severe and lasting aplasia after infusion of donor leukocytes. In two patients - one with extramedullary and one with marrow relapse after a sex-mismatched transplantation - we analyzed hematopoietic chimerism by cell sorting and bone marrow cultures. CD34-positive cells, CD4-CD8-positive cells, committed progenitors, and LTC-IC were of donor origin, as demonstrated by two-color fluorescence in situ hybridization (FISH). Additionally, in relapse complete donor T-cell chimerism was seen. In contrast, plasma cells were of recipient origin in the patient who had a relapse in the bone marrow. Both patients were treated with infusions of donor leukocytes from their original donor. Neither patient suffered myelosuppression, and one achieved a stable complete remission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460352     DOI: 10.1007/s002770050532

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

1.  Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Y Fløisand; L Brinch; T Gedde-Dahl; G E Tjønnfjord; I Dybedal; H Holte; D Heldal; D Torfoss; E Aurlien; G F Lauritzsen; A Fosså; G Lehne; E Baggerød; G Kvalheim; T Egeland; M R Bishop; D H Fowler; A Kolstad
Journal:  Bone Marrow Transplant       Date:  2012-04-23       Impact factor: 5.483

2.  EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.

Authors:  S Jamshed; D H Fowler; S S Neelapu; R M Dean; S M Steinberg; J Odom; K Bryant; F Hakim; M R Bishop
Journal:  Bone Marrow Transplant       Date:  2010-07-26       Impact factor: 5.483

3.  Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

Authors:  Rachel B Salit; Daniel H Fowler; Robert M Dean; Steven Z Pavletic; Frances T Hakim; Seth M Steinberg; Nancy T Hardy; Claude Sportes; Ronald E Gress; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2013-08-13       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.